CD274 and breast cancer: Besides TILs and PD-L1 expression, several other components of BC immune infiltrates have been investigated as potential clinically relevant biomarkers, including the evaluation of specific TIL subsets, TLS and other key players of both the innate and adaptive immune responses, such as NKs, TAMs and DCs.